Catheter ablation of atrial fibrillation

Atrial fibrillation is a common arrhythmia associated with significant morbidity including angina, heart failure and stroke. Medical therapy remains suboptimal with significant side effects and toxicities, as well as a high recurrence rate. Catheter ablation or modification of the atrio-ventricular node with pacemaker implantation provides rate control but subjects the patient to the risks of an implantable device and does nothing to reduce the risk of stroke. Pulmonary vein antrum isolation offers a nonpharmacologic means of restoring sinus rhythm, thereby eliminating the morbidity of atrial fibrillation and the need for anti-arrhythmic drugs.     

Catheter ablation for cardiac arrhythmias

The safety and efficacy of catheter ablation for treatment of most types of cardiac arrhythmias are well established. These arrhythmias and arrhythmia substrates include AVNRT, accessory pathways, focal atrial tachycardia, atrial flutter, idiopathic ventricular tachycardia, and bundle-branch re-entry. Catheter ablation is considered as an alternative to pharmacologic therapy in the treatment of these cardiac arrhythmias.     

Catheter ablation of electrical storm

Electrical storm (ES) is defined as the occurrence of ≥ three distinct episodes of ventricular arrhythmia (VA) in patients with implanted defibrillators within 24 h. Whereas conventional strategies for acute rhythm stabilization may be effective in some patients the occurrence of ES impairs survival and predicts recurrent VA. Catheter ablation in the setting of ES is complex and involves decisive strategies for individualized ablation approaches adapted to the patient's cardiac abnormalities. Success rates have been documented to be between 79 and 94% in larger studies and effective ablation improves survival and freedom from any VA. Ablation should be considered early in the treatment plan and availability may be improved by interhospital collaboration with highly experienced VA intervention centers.     

Catheter ablation of atrial fibrillation with a novel,duty-cycled ablation system

Atrial fibrillation (AF) is the most common arrhythmia experienced in clinical practice (approx. 1% predominance in the adult population). Unfortunately, long-term efficacy of antiarrhythmic drug therapy is disappointing and could cause serious side effects. Radiofrequency (RF) catheter ablation has emerged as an important therapeutic option for drug refractory patients. However, the development in ablation strategies remains complex with often lengthy procedures. This study investigates whether a novel multielectrode catheter, delivering duty-cycled bipolar/unipolar RF energy, is feasible and safe. Therefore, 81 consecutive patients with paroxysmal or persistent AF has been analyzed. Pulmonary vein isolation with the pulmonary vein ablation catheter was safe with short fluoroscopy/procedural time and good clinical efficacy at 6 months (stable sinus rhythm in 78% of patients).     

Catheter ablation of atrial fibrillation: long-term outcomes

The benefits of percutaneous coronary intervention (PCI) can be offset by periprocedural complications such as acute vessel closure and stent thrombosis in the absence of adequate antiplatelet and antithrombotic therapy. Additionally, conditions occurring after 30 days post-PCI, such as in-stent restenosis or late stent thrombosis can occur. Excess antithrombotic therapy, on the other hand, carries a risk of major gastrointestinal or intracranial bleeding as well as vascular access site bleeding complications. In this review, evidence related to the various pharmacological agents for reduction of stent thrombosis available to clinicians during and after PCI will be explored.     

Catheter ablation of atrial fibrillation: long-term outcomes

Atrial fibrillation is the most common arrhythmia faced in clinical practice with a substantial impact on morbidity, mortality, and heathcare expenditures. Patients with atrial fibrillation in which a rhythm control strategy is desired to improve quality of life have had limited options. The discovery of the role of pulmonary vein triggers has led to the development of catheter ablation techniques that have shown promising short-term success rates. Long-term outcomes were until recently, lacking. These results confirm the inherently recurrent nature of atrial fibrillation and the need for multiple procedures to achieve reasonable long-term successful maintenance of sinus rhythm.     

Catheter ablation of atrial flutter and atrial fibrillation

Within the past 20 years, refinements in electrophysiologic mapping techniques have provided a better understanding of the pathophysiology of atrial flutter and atrial fibrillation (AF), which resulted in the development of catheter ablation techniques for this arrhythmias. Nowadays, catheter ablation has become the first line treatment of recurrent symptomatic or hemodynamically significant atrial flutter. In contrast, catheter ablation of AF is still an investigational procedure and should be restricted to patients with symptomatic AF who have been refractory to multiple antiarrhythmic drugs. In symptomatic patients with AF and an uncontrolled ventricular rate who have failed treatment with several antiarrhythmic drugs and who do not fit for primary catheter ablation of AF atrioventricular junction ablation with prior pacemaker implantation is recommended.     

Catheter intramural needle radiofrequency ablation creates deeper lesions than irrigated tip catheter ablation

Radiofrequency ablation of the left ventricle using an endocardially placed electrode is unable to reliably create transmural lesions even with active electrode cooling. To produce deeper radiofrequency lesions, the authors developed and tested a prototype intramural needle ablation catheter that had a distal 1.1-mm diameter straight needle that could be advanced 12 mm into the myocardium. Freshly excised hearts from eight male sheep were perfused and superfused with oxygenated ovine blood. Ablations were performed for 60 seconds with the prototype catheter and a conventional 5-mm irrigated tip ablation catheter at target temperatures of 90 degrees C and 50 degrees C, respectively. The ablation lesions were bisected and stained with blue tetrazolium to assess lesion geometry. The irrigated tip ablation catheter required significantly more power than the intramural needle ablation catheter (37.7 +/- 7.3 vs 6.4 +/- 2.1 W, P < 0.01). Intramural needle lesions were significantly deeper (12.5 +/- 3.0 mm vs 8.3 +/- 2.1 mm, P < 0.01) but less wide (3.9 +/- 1.1 mm vs 11.5 +/- 2.0 mm, P < 0.01) than irrigated tip lesions. There was a high incidence of crater formation (74%), popping (45%), and myocardial charring (29%) during irrigated tip ablation; these phenomena were not observed during intramural needle ablation. The intramural needle ablation catheter creates significantly deeper but narrower lesions without evidence of tissue boiling. This technology may be particularly useful for ablation of ventricular tachycardia originating from regions where tissue depth is increased, like the ventricular septum.     

Catheter ablation for ventricular tachycardia: indications and techniques

Ventricular tachycardia (VT) may be secondary to many different underlying pathophysiologies. The nature of the underlying disorder determines amenability to catheter ablation, thus, dictating the circumstances under which it should be undertaken. The differing substrates also influence the choice of techniques that are used. The most intensively studied clinical subgroup of VT is re-entrant VT in the setting of ischemic heart disease. The approach to ablation in such patients is discussed in detail. Subsequent discussion focuses on other clinically encountered varieties of VT and the ablation methods used in each individual disease state.     

Catheter ablation for atrial fibrillation: mechanism-based curative treatment

The considerable cumulative morbidity and mortality burden resulting from atrial fibrillation has prompted renewed efforts to seek curative and widely applicable therapies. Currently used drugs are not only frequently ineffective at eliminating fibrillation, but may actually be life threatening. Extensive surgery involving both atria has shown that atrial fibrillation can be eliminated in most, if not all, patients, but at a significant cost. The recent discovery of the pivotal role that myocardial extensions into the pulmonary veins play in the initiation, and probably also the maintenance, of atrial fibrillation, has provided a relatively limited target conducive to catheter-based interventions. In experienced hands, paroxysmal atrial fibrillation can be eliminated in more than 85% of patients by a percutaneous intervention lasting less than 3 h with an attendant nonlethal complication risk of 1 to 2%. Thromboembolic complications and pulmonary vein stenosis are the principal complications that may result from this treatment, but their incidence is decreasing. Success rates in patients with persistent or permanent atrial fibrillation are lower, and it is anticipated that increased understanding of the underlying mechanisms will allow doctors to identify those subsets with the greatest potential for benefit from percutaneous catheter-based interventions. Such progress may allow doctors to extend the benefits of eliminating atrial fibrillation to the widest possible range of patients with this recalcitrant disorder.     

Catheter ablation for atrial fibrillation: mechanism-based curative treatment

The considerable cumulative morbidity and mortality burden resulting from atrial fibrillation has prompted renewed efforts to seek curative and widely applicable therapies. Currently used drugs are not only frequently ineffective at eliminating fibrillation, but may actually be life threatening. Extensive surgery involving both atria has shown that atrial fibrillation can be eliminated in most, if not all, patients, but at a significant cost. The recent discovery of the pivotal role that myocardial extensions into the pulmonary veins play in the initiation, and probably also the maintenance, of atrial fibrillation, has provided a relatively limited target conducive to catheter-based interventions. In experienced hands, paroxysmal atrial fibrillation can be eliminated in more than 85% of patients by a percutaneous intervention lasting less than 3 h with an attendant nonlethal complication risk of 1 to 2%. Thromboembolic complications and pulmonary vein stenosis are the principal complications that may result from this treatment, but their incidence is decreasing. Success rates in patients with persistent or permanent atrial fibrillation are lower, and it is anticipated that increased understanding of the underlying mechanisms will allow doctors to identify those subsets with the greatest potential for benefit from percutaneous catheter-based interventions. Such progress may allow doctors to extend the benefits of eliminating atrial fibrillation to the widest possible range of patients with this recalcitrant disorder.     

Catheter ablation for ventricular tachycardia: indications and techniques

Ventricular tachycardia (VT) may be secondary to many different underlying pathophysiologies. The nature of the underlying disorder determines amenability to catheter ablation, thus, dictating the circumstances under which it should be undertaken. The differing substrates also influence the choice of techniques that are used. The most intensively studied clinical subgroup of VT is re-entrant VT in the setting of ischemic heart disease. The approach to ablation in such patients is discussed in detail. Subsequent discussion focuses on other clinically encountered varieties of VT and the ablation methods used in each individual disease state.     

Catheter ablation of ventricular tachycardia in structurally normal hearts

Ventricular tachycardia (VT) in patients without structural heart disease can be observed in 10% of patients presenting with ventricular arrhythmias. These VTs are characterized by QRS morphology, ventricular origin and their response to pharmacologic agents. It is essential to rule out structural heart disease in this population as this can significantly alter the management and the long-term prognosis. These VTs generally have a benign course and therapeutic options are aimed at relieving symptoms related to the arrhythmia. Medical therapy is effective in many patients and radiofrequency offers a cure to those who are refractory to medical therapy. Careful attention to the electrocardiogram can help localize the origin of the VTs, which is crucial when planning an ablation strategy.     

Carto三维标测指导下室性心律失常射频消融术的护理难点与对策

目的 探讨Carto三维标测指导下室性心律失常射频消融术围手术期护理难点与对策。 方法 对24例动员行Carto三维标测射频消融术患者的资料进行分析,总结术前动员成败的原因、术中术后护理难点及其对策。 结果 Carto三维标测射频消融术围手术期护理难点有：患者对新技术缺乏信任感,拒绝率高;术中配合要求高,配合难度大;术后卧床时间长,患者舒适度低。对策：术前强化健康教育和心理干预是保证患者依从性和手术顺利进行的基础;术中熟练的配合技巧是手术安全的保障;术后提供精细化护理服务是提高患者舒适度的必要条件。结论 Carto三维标测射频消融术是一项新兴技术,需要对患者围绕Carto三维标测新技术进行强化健康教育和心理护理干预,对参与手术的护士需要进行专项技能培训才能顺利完成对Carto三维标测射频消融术的密切配合。     

Catheter ablation of atrial flutter in a heart transplant recipient

In the transplanted heart with biatrial anastomosis, atrial flutter is common and is amenable to catheter ablation. Although this arrhythmia is isthmus dependent, the unique atrial architecture with a suture line through the inferior vena cava-tricuspid annulus isthmus makes the substrate atypical. A cardiac transplant recipient with atrial flutter underwent successful catheter ablation. Five weeks after the procedure, the patient died of a myocardial infarction. The autopsy and histological findings are described and correlated with the electroanatomic map obtained during the ablation. Due to the atrial suture lines, atrial flutter following cardiac transplantation is an isthmus dependent arrhythmia with a different arrhythmogenic substrate. The electrical isthmus (atrial tissue from the tricuspid annulus to the suture line) in these hearts is smaller than the anatomic isthmus.